Trial Profile
Long Term Safety Follow-up of REMICADE (RESULTS).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2014
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms RESULTS
- Sponsors Centocor
- 03 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Mar 2009 New trial record